A Digital Platform for the Development of Next-Generation Antibody Drug Conjugates (ADCs) and Other Antigen-Targeting Conjugates

Basel, Switzerland
May 16, 2024

Antibody Drug Conjugates (ADCs) use antibodies to achieve targeted delivery of therapeutic cargoes to specific cell populations and tissues. In oncology, ADCs are used to selectively eliminate tumors while reducing the off-target effects associated with conventional chemotherapy. Here, we present how Genedata Biologics® supports and accelerates the full ADC discovery process from antibody screening and engineering to antibody expression, purification, drug conjugation, and reporting of ADC-specific analytics (e.g. DAR, drug distribution, homogeneity). The platform enables the automated generation, registration, and tracking of large panels of ADC candidates and incorporates results from analytics and functional assays in one integrated system, thereby substantially increasing throughput and efficiency of the ADC discovery process. Other next-generation antigen-targeting conjugates, including bi-specific ADCs, alternative scaffolds (e.g. scFVs, DARPins), and novel payloads (e.g. oligonucleotides, antibiotics) are also supported by the system to accelerate the application of these new technologies.